PCSK9-LDLR in vitro Binding Assay Kit 供应商 Abnova 产品货号 KA1074 产品报价 ￥询价/1Kit 产品说明书 点击查看 购买方式 在线支付宝及网银支付、支票、现金、电汇,或拨打全国免费服务电话4006800868与我们联系。 产品新闻 背景资料 PCSK9-LDLR in vitro Binding检测试剂盒产品为Abnova旗下提供的高品质试剂盒产...
4) PCSK9-DLR相互作用的体外表征。 作为Abnova全国总代理,艾美捷科技强烈推荐Abnova热销产品PCSK9-LDLR体外结合测定试剂盒。产品仅用于科研,不可用于临床诊断。 PCSK9-LDLR体外结合测定试剂盒: 中文名称:PCSK9-LDLR体外结合测定试剂盒 英文名字:PCSK9-LDLR in vitro Binding Assay Kit 供应商:Abnova 产品货号:KA1074...
使用pcsk9-ldlr体外结合活性检测试剂盒(circulex pcsk9-ldlr in-vitro binding assay kit,购自mbl life science)对待测化合物进行体外pcsk9-ldlr ppi抑制活性评价,化合物pep2-8(氨基酸序列ac-tvftsweeyldwv-nh2,由synpeptide inc.定制合成,hplc纯度≥98%)为阳性对照。详细实验操作流程按照试剂盒的使用说明,略有...
英文名称: PCSK9[Biotinylated]-LDLR Binding Assay Kit 总访问: 59 国产/进口: 进口 半年访问: 7 产地/品牌: BPS 产品类别: 其他生物试剂 规格: 96 rxns. 最后更新: 2024-12-5 货号: 72002 CAS 号: 参考报价: 11270 立即询价 电话咨询
The ability of vaccine-generated antibodies for inhibition of the PCSK9/LDLR interaction in vitro was evaluated using PCSK9-LDLR in vitro binding assay kit (CircuLex™, Cy-8150, MBL, Woburn, MA). The principle of the assay is based on the binding between recombinant His-tagged PCSK9 and...
免费查询更多pcsk9-ldlr in vitro binding assay试剂盒详细参数、实时报价、行情走势、优质商品批发/供应信息等,您还可以发布询价信息。
Protein concentration was determined using the bicinchoninic acid protein assay kit (Interchim, Montluçon, France). Proteins were transferred onto a Protran nitrocellulose membrane (Schleicher and Shuell, Dassel, Germany), probed with polyclonal chicken anti-LDLr antibody (RDI, Flanders, NJ) or ...
2.2.3. In vitro PCSK9-LDLR binding assay Compounds were screened for their inhibitory activity against the PCSK9-LDLR interaction using a CircuLex PCSK9-LDLR in vitro binding assay kit according to the manufacturer’s instructions. Briefly, stock solutions of test compounds were prepared as 10 ...
Crystal structures have shown that this Ser127 residue does not interact directly with the LDLR [19]. Longitudinal population studies have shown significant reduction in the risk of coronary heart disease in ‘loss-of-function’ PCSK9 carriers [20,21]. Reduced plasma PCSK9 concentrations for at ...
Despite reports on the efficacy of proprotein convertase subtilisin-Kexin type 9 (PCSK9) inhibitors as a potent lipid-lowering agent in various large-scale clinical trials, the anti-atherogenic properties of PCSK9 inhibitors in reducing PCSK9 and atherogenesis biomarkers via the NF-ĸB and eNOS ...